 Home > Biochemistry News > Biotechnology News > Targeted editing, inhibition, and degradation of mRNA ADARx Pharmaceuticals receives US$7,500 in assistance

Targeted editing, inhibition, and degradation of mRNA ADARx Pharmaceuticals receives US$7,500 in assistance

 Last Update: 2021-10-11
 Source: Internet
 Author: User

Tags

human adipose tissue

mrna sequence dna

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 8, 2021, ADARx Pharmaceuticals announced the completion of a US$75 million Series B financing
.

The funds from this round of financing will be used to advance ADARx's technology platform for targeting mRNA, including editing, inhibiting or degrading mRNA, and tissue-specific delivery technologies

ADARx is developing a proprietary platform targeting RNA
.

Using the RNA editing method of this technology platform, researchers can use existing intracellular mechanisms to precisely edit a base against the RNA sequence to develop stable and efficient precision therapies

In addition, ADARx has developed a liver delivery technology using the characteristics of N-acetylgalactosamine (GalNAc)
.

GalNAc is a sugar molecule that recognizes and binds to the cell surface asialoglycoprotein receptor (ASGPR), which is highly expressed in the liver, allowing the liver to ingest therapeutic drugs in a targeted manner

Reference materials:

[1] ADARx Raises $75 Million to Advance Growing Pipeline.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.